Used in targeted cancer immunotherapy, particularly for hematologic malignancies. Binds selectively to TSPAN26 (CD37) antigen expressed on B-cell lymphocytes, enabling immune-mediated destruction of malignant cells. Employed in antibody-drug conjugates (ADCs) and as a component in monoclonal antibody therapies to enhance specificity and reduce off-target effects. Shows promise in clinical development for non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Also utilized in diagnostic and research settings to detect CD37 expression in cell populations.